Device/Drug Borderline: Gray Areas Remain Despite New EU Guidance
The regulation of products on the drug/device borderline has always been complex. New EU guidance aims to provide clarification, but some difficult and nuanced decision-making is still left to the manufacturer.
You may also be interested in...
Medtech Insight spoke to the CEOs of two companies that recently had very different experiences with the new European IVDR and MDR regulations to gauge their thoughts on any potential commercial impacts.
The ongoing availability of many medical devices in Switzerland is threatened even more severely than in the EU. Medtech Insight spoke to two key life science experts to understand why this is and to hear the solutions they are proposing.
The Council of EU’s agenda for the critical upcoming health council meeting confirms position of EU Medical Device Regulation in day’s running, along with other key health issues.